Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.34)
# 2,677
Out of 5,182 analysts
118
Total ratings
44.76%
Success rate
-1.82%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Buy | $164 → $200 | $128.89 | +55.17% | 18 | Apr 7, 2026 | |
| BIIB Biogen | Maintains: Buy | $230 → $245 | $172.97 | +41.64% | 23 | Apr 1, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $20 → $18 | $5.53 | +225.50% | 6 | Mar 26, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $36 → $60 | $34.33 | +74.77% | 6 | Mar 20, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $35 | $26.73 | +30.94% | 1 | Mar 19, 2026 | |
| CLNN Clene | Maintains: Buy | $48 | $6.11 | +685.60% | 7 | Mar 13, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.72 | +148.09% | 5 | Jan 6, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $9.47 | +153.43% | 7 | Nov 6, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.64 | +284.62% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $1.59 | +969.18% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $27 | $3.83 | +604.96% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.74 | +220.86% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.06 | +7,447.17% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.74 | +51.79% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.17 | +1,535.77% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $30.82 | - | 2 | Jan 31, 2017 |
Neurocrine Biosciences
Apr 7, 2026
Maintains: Buy
Price Target: $164 → $200
Current: $128.89
Upside: +55.17%
Biogen
Apr 1, 2026
Maintains: Buy
Price Target: $230 → $245
Current: $172.97
Upside: +41.64%
COMPASS Pathways
Mar 26, 2026
Maintains: Buy
Price Target: $20 → $18
Current: $5.53
Upside: +225.50%
Stoke Therapeutics
Mar 20, 2026
Maintains: Buy
Price Target: $36 → $60
Current: $34.33
Upside: +74.77%
MapLight Therapeutics
Mar 19, 2026
Initiates: Buy
Price Target: $35
Current: $26.73
Upside: +30.94%
Clene
Mar 13, 2026
Maintains: Buy
Price Target: $48
Current: $6.11
Upside: +685.60%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.72
Upside: +148.09%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.47
Upside: +153.43%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.64
Upside: +284.62%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $1.59
Upside: +969.18%
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $3.83
Upside: +604.96%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.74
Upside: +220.86%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.06
Upside: +7,447.17%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.74
Upside: +51.79%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.17
Upside: +1,535.77%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $30.82
Upside: -